Loading
A phase 1/2 trial of Rituximab, Cyclophosphamide, Doxorubicin in diffuse large b-cell lymphoma and follicular lymphoma, run by Genmab, active and no longer recruiting.
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) is a phase 1/2 interventional study registered as NCT04663347 by Genmab, with 543 participants enrolled, started 2020-11-03 and due to reach its primary completion in 2027-09-30. Interventions recorded: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, gemcitabine and oxaliplatin. Conditions listed: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma. No results are recorded here; the registry entry is the source.
Shares Genmab, Prednisone, Vincristine, Rituximab.
Shares Genmab, Lenalidomide, Prednisone, Vincristine.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Lenalidomide, Prednisone, Vincristine, Rituximab.
Shares Genmab, Prednisone, Vincristine, Rituximab.
Shares Lenalidomide, Vincristine, Rituximab, Follicular lymphoma.
Shares Lenalidomide, Vincristine, Rituximab, Follicular lymphoma.
Shares Prednisone, Vincristine, Rituximab, Follicular lymphoma.